This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pharmaceuticals: Archive
Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure?
by Ekta Bagri
CYTK enters a new era after Myqorzos FDA approval, with early US uptake, European expansion and lifecycle studies fueling its commercial momentum.
CYTKNegative Net Change BMYNegative Net Change EWTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
How a Rival's Clinical Setback Sent BBIO Stock to a 52-Week High
by Sundeep Ganoria
BridgeBio Pharma hit a 52-week high after a rival's phase III setback boosts confidence in Attruby's competitive position in ATTR-CM.
BBIONegative Net Change AZNNegative Net Change PFENegative Net Change
biotechs medical pharmaceuticals
FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data
by Zacks Equity Research
Forte Biosciences stock soars after early-stage data show FB102 significantly improves facial depigmentation in vitiligo with a favorable safety profile.
FBRXPositive Net Change NVAXNegative Net Change AMRNNegative Net Change LQDANegative Net Change
biotechnology biotechs medical pharmaceuticals
NVO Rallies 11% in a Month: How Should Investors Play the Stock?
by Ahan Chakraborty
Novo Nordisk stock gains 11% in a month as Wegovy access expands and U.K. approval boosts optimism, but rising competition and earnings pressure cloud the outlook.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
EXEL Stock Soars 26.8% in Three Months: Is There More Room for Growth?
by Ekta Bagri
Exelixis' zanzalintinib faces a setback, but an FDA review, phase III trials and Cabometyx momentum keep investors focused on its growth path.
EXELNegative Net Change RHHBYNegative Net Change MRKNegative Net Change
biotechnology medical pharmaceuticals
TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know
by Zacks Equity Research
Tvardi Therapeutics stock jumps this week as phase I data for TTI-109 highlight improved tolerability, target engagement and support plans for mid-stage development.
TVRDNegative Net Change NVAXNegative Net Change AMRNNegative Net Change LQDANegative Net Change
biotechnology biotechs medical pharmaceuticals
Buyout Buzz Around VKTX Is Back: What's Fueling the Speculation?
by Sundeep Ganoria
Viking Therapeutics' expanding obesity pipeline and upcoming VK2735 data reignite buyout speculation as investors weigh its growing strategic appeal.
VKTXNegative Net Change NVOPositive Net Change LLYNegative Net Change
biotechs medical pharmaceuticals
AstraZeneca's Stock Drops on Wainua's Setback in ATTR-CM Study
by Zacks Equity Research
AZN shares tumble after Wainua missed the primary endpoint in a late-stage ATTR-CM study, raising questions about its expansion into a larger market.
AZNNegative Net Change ALNYNegative Net Change IONSNegative Net Change BBIONegative Net Change
biotechs medical pharmaceuticals
Top Research Reports for Tesla, Bank of America & Merck
by Mark Vickery
Tesla, Bank of America and Merck lead today's featured research, highlighting growth drivers, risks and outlooks shaping these widely watched stocks.
BACPositive Net Change MRKNegative Net Change DKSPositive Net Change TSLAPositive Net Change EVIPositive Net Change NETNegative Net Change DDOGNegative Net Change ONFONegative Net Change
auto-tires-trucks finance industrial-products pharmaceuticals retail
DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?
by Zacks Equity Research
Denali Therapeutics surges on Avlayah???s FDA approval, PRV sale and pipeline progress, but partnership changes and trial setbacks remain in focus.
DNLINegative Net Change SNYNegative Net Change BIIBPositive Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals